Assessing Functional Quality of Single TILs for Correlative Immunotherapy Biomarkers

Learn how using Single-Cell PSI  helps you reveal mechanisms in the Tumor Microenvironment.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Highlight the challenges in functional characterization of TILs in checkpoint and combination therapies
Describe the workflow for functional single-cell analysis from both solid tumor TILs as well as patient PBMC
Predict patient response to checkpoint therapy using PSI as a biomarker in solid tumor TILs, as well as correlate response from these solid tumor TILs with PSI from peripheral blood
A Deeper Look

More about this

Overcoming Challenges in Checkpoint Combination Therapies

Checkpoint inhibitor blockade therapy has rapidly advanced and is now established as a powerful way to manage various malignant tumors.

Despite the promising outcomes, there are a significant number of patients who do not respond to these immunotherapies.

Download this App Note to learn how IsoPlexis’ PSI helps you overcome these challenges with a wide range of applications in checkpoint and combination therapy research.

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Get the